| Study Name | Description | Trial Category | Trial SubCategory |
|---|---|---|---|
| The TESLA Trial | Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke | Neurosciences | Stoke |
| URCC 16070 | Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer | Cancer | Breast |
| A151216 (ALCHEMIST) | Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) | Cancer | Lung |
| Agendia FLEX | The objective of this study is to create a large scale, population-based registry of full genome expression data and clinical data to investigate new gene associations with prognostic and/or predictive value | Cancer | Breast |
| EA6134 | A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma | Cancer | Melanoma |
| EA6141 | Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma | Cancer | Melanoma |
| EAY131 (MATCH) | A Molecular Analysis for Therapy Choice (MATCH) - This study is a type of basket trial designed with the flexibility to open and close sub-protocols. Patients enrolled on study will have a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial will be offered treatment on MATCH. *Now using outside molecular reports which tumor must be collected within 6 months with no intervening treatment. Foundation One reports will now notify MATCH of molecular matches. | Cancer | Genomic testing based trial |
| NRG BR003 | A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer | Cancer | Breast |
| NRG-GU002 | Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel | Cancer | Prostate |
| S0820 - Prevention of High-Risk Colorectal Polyps and New Colorectal Cancers | PACES S0820 is a study to determine the efficacy of certain drugs in the prevention of high-risk colorectal polyps and new colorectal cancers in patients with previously treated colorectal cancer. | Cancer | Gastro-Intestinal |
| S1507 | A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies | Cancer | Lung |
| S1609 - DART | DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in rare tumors. Single arm nivolumab and ipilimumab treating patients with rare tumors | Cancer | Rare Tumor |
| TAPUR Study for Advanced Cancers | The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. For more information please visit http://www.tapur.org/patients | Cancer | Genomic testing based trial |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.